In the past 3 to 5 years there have been numerous requests for nootropic studies. This is something that has been confirmed by several analytical labs. Josh Baisley, B.Sc., director of clinical trials at Nutrasource talked about this subject.
He works at one of the labs that help companies with various clinical trials or product testing. He explained that the high demand for dietary supplement nootropics is caused by the side effects of various pharmaceutical agents.
“There is [also] a lack of effective pharmaceutical therapies for more severe conditions such as dementia and Alzheimer’s which appear more prevalent due to the aging population,” Baisley explained. Because of that, consumers began to ask for more dietary supplements and natural products.
KGK Science also observed the same trend when it comes to nootropic dietary supplements testing. “The changes are also a reflection of the 21st century North American population,” she told us. “Cognition and stress is an issue with baby boomers becoming a sandwich generation, the transient nature of jobs, and the demand for keeping up with the ever-changing face of technology.”
That is especially true since, with all the distractions people have around them, one can easily get sidetracked and momentarily lose focus. For most adults, for instance, it can be difficult to juggle many things, especially if you wear a lot of hats every day. And with that, the creation of supplements such as Vyvamind can actually be beneficial.
Nootropics are believed to help give focus and coherence. Having dietary supplements that could enhance the performance of anyone studying, working, or doing what they’re passionate about can go a long way in giving people alternatives that could work for them. And with smart drugs, there could be an increase in focus, clarity, and creativity. Thus, more people are able to accomplish more high-quality work output.
Proving the efficacy of a nootropic supplement
Until now, scientists have been using a randomized controlled trial model for all nootropic testing. However, according to Dr. Mal Evans, scientific director at KGK Science, this model led to some trials that had high “proportions of false negatives.”
“There is [also] a lack of effective pharmaceutical therapies for more severe conditions such as dementia and Alzheimer’s which appear more prevalent due to the aging population,” Evans added. The company came with a new global index named Cog-GI (Cognitive Global Index). This index combines endpoints from studies of dietary supplements.
“There is [also] a lack of effective pharmaceutical therapies for more severe conditions such as dementia and Alzheimer’s which appear more prevalent due to the aging population,” Evans concluded.